drugset / Trial / NCT04298333
Dose-finding Study of BP-C1 in Patients With Stage IV Breast Cancer
Phase 1
Completed
18 enrolled
Meabco A/S
Meddoc · collabMeddoc Research Indonesia Ltd · collabMeddoc Research Taiwan Ltd · collabNorwegian University of Life Sciences · collab
SequentialOpen-labelSupportive care
Summary
The purpose of this study is to estimate the cumulative Maximum Tolerated Dose (MTD) and Minimum Efficient Dose (MED) of BP-C1 in the short-term treatment of metastatic breast cancer patients.
Timeline
- Start
- 2009-06-27
- Primary completion
- 2011-01-04
- Completion
- 2011-01-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BP-C1 | Other / unclassified | 0.02 mg/kg | Intramuscular |
| Subject | BP-C1 | Other / unclassified | 0.03 mg/kg | Intramuscular |
| Subject | BP-C1 | Other / unclassified | 0.035 mg/kg | Intramuscular |